Back to Search
SYDNIE JONES, MD
MD
Neurology Physician
NPI: 1275128134Individual
Specialties, Licenses & Credentials
General Practice Physician
General Practice
Code: 208D00000X
35462(NE)
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Neurology PhysicianPrimary
Psychiatry & Neurology — Neurology
Code: 2084N0400X
35462(NE)
Research & Publications (20)
Maturation of granule cell dendrites after mossy fiber arrival in hippocampal field CA3.
PMID 12722981·Hippocampus·2003
7-preclinical
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
PMID 19204201·J Clin Oncol·2009
3-trial
The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.
PMID 19073509·Clin Breast Cancer·2008
4-observational
Considerations in treatment choice for metastatic breast cancer.
PMID 18224392·Breast Cancer·2008
8-other
Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy.
PMID 17947724·J Clin Oncol·2007
4-observational
Direct admission to cardiology for patients hospitalized for atrial fibrillation reduces length of stay and increases guideline adherence.
PMID 16808143·Mil Med·2006
8-other
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
PMID 17135639·J Clin Oncol·2006
3-trial
Exemestane as adjuvant treatment of early breast cancer: intergroup exemestane study/tamoxifen exemestane adjuvant multicenter trials.
PMID 16595025·Clin Breast Cancer·2006
4-observational
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
PMID 16110015·J Clin Oncol·2005
3-trial
Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.
PMID 15865850·Clin Breast Cancer·2005
4-observational
Fulvestrant: an estrogen receptor antagonist that downregulates the estrogen receptor.
PMID 14613022·Semin Oncol·2003
6-review
Antiaromatase agents: evolving role in adjuvant therapy.
PMID 12020394·Clin Breast Cancer·2002
6-review
Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer.
PMID 12123539·Clin Breast Cancer·2002
3-trial
A new estrogen receptor antagonist--an overview of available data.
PMID 12353819·Breast Cancer Res Treat·2002
6-review
Low proliferative rate of invasive node-negative breast cancer predicts for a favorable outcome: a prospective evaluation of 669 patients.
PMID 11899353·Clin Breast Cancer·2001
8-other
Dissecting structure-function interactions in acute optic neuritis to investigate neuroplasticity.
PMID 19662659·Hum Brain Mapp·2010
8-other
Myristoylated alanine-rich C-kinase substrate (MARCKS) protein regulation of human neutrophil migration.
PMID 19574534·Am J Respir Cell Mol Biol·2010
8-other
The process of recovery from bipolar I disorder: a qualitative analysis of personal accounts in relation to an integrative cognitive model.
PMID 19523280·Br J Clin Psychol·2010
8-other
Laparoscopic lumbar hernia repair in a child with lumbocostovertebral syndrome.
PMID 19645602·J Laparoendosc Adv Surg Tech A·2010
5-case
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3551 ROGER BROOK DR, JBSA- FT SAM HOUSTON, SAMMC, MCHE-ZDM-M, INTERNAL MEDICINE RESIDENCY
SAN ANTONIO, TX 78234 - Phone
- (210) 292-7805
Quick Facts
- NPI
- 1275128134
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 3
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile